普莱柯生物工程股份有限公司关于预计2026年度日常关联交易的公告

Core Viewpoint - The announcement details the expected daily related transactions for 2026 by Pulaike Biological Engineering Co., Ltd., emphasizing that these transactions are necessary for the company's operations and will not harm the interests of shareholders, particularly minority shareholders [2][3]. Group 1: Daily Related Transactions Overview - The estimated amount for daily related transactions in 2026 is 39.24 million yuan, accounting for 1.49% of the audited net assets for 2024, and does not require shareholder meeting approval [3]. - The board of directors, including independent directors, has reviewed and approved the proposal, confirming that the transactions are fair and reasonable, and will not affect the company's independence or ongoing operations [3][14]. Group 2: Related Parties and Relationships - The related parties include several pet hospitals and clinics, all controlled by a parent company, with the actual controller of Pulaike also controlling these entities, establishing a clear related party relationship [7][11]. - Other related parties include Zhongke Gene and its subsidiaries, which are also under the same actual control as Pulaike, further solidifying the interconnectedness of these entities [9][11]. Group 3: Transaction Details and Pricing Policies - The main content of the daily transactions includes the sale of goods, provision of leasing services, purchase of goods, and acceptance of labor services, with pricing based on market rates or cost-plus methods to ensure fairness [13]. - The transactions are designed to meet the company's operational needs and are executed in accordance with relevant contracts, ensuring that they do not harm the company's interests or financial status [14].